stockrowDexCom, Inc.
DXCM Healthcare Medical Devices
DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024.
- Revenue
- +11.2%
- EPS
- 0.00%
- Free cash flow
- −52.9%
- Total debt
- +0.31%
Quarter to September 2026, against a year earlier
Follow DXCM
Alert me
DexCom, Inc. (DXCM) EPS (diluted)
DexCom, Inc.'s EPS (diluted) for fiscal 2025 was $2.09, up 47.2% from $1.42 in fiscal 2024. Over the twelve months to 30 September 2026 it was $2.55. Over the past ten years it has ranged from −$0.36 (fiscal 2018) to $2.09 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 4 consecutive fiscal years. DexCom, Inc. ranks 17th of 147 Medical Devices companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $2.09 | 47.18% |
| FY2024 | $1.42 | 9.23% |
| FY2023 | $1.30 | 58.54% |
| FY2022 | $0.82 | 54.72% |
| FY2021 | $0.53 | (58.10%) |
| FY2020 | $1.27 | 360.00% |
| FY2019 | $0.28 | — |
| FY2018 | −$0.36 | — |
| FY2017 | −$0.15 | — |
| FY2016 | −$0.20 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.72 | 12.50% |
| Jun 2026 | $0.64 | 25.49% |
| Mar 2026 | $0.51 | (25.00%) |
| Dec 2025 | $0.68 | (2.86%) |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| STE STERIS plc compare | $8.43 |
| GEHC GE HealthCare Technologies Inc. compare | $4.76 |
| ZBH Zimmer Biomet Holdings, Inc. compare | $3.96 |
| DXCM DexCom, Inc. | $2.55 |
| BSX Boston Scientific Corporation compare | $2.36 |
| EW Edwards Lifesciences Corporation compare | $1.77 |
| PHG Koninklijke Philips N.V. compare | $1.17 |
| SNN Smith & Nephew SNATS, Inc. compare | $1.13 |
| GKOS Glaukos Corporation compare | −$2.94 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on DXCM
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement